These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 25768916)

  • 1. Targeting the human androgen receptor gene with platinated triplex-forming oligonucleotides.
    Graham MK; Brown TR; Miller PS
    Biochemistry; 2015 Apr; 54(13):2270-82. PubMed ID: 25768916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of transcription by platinated triplex-forming oligonucleotides.
    Graham MK; Miller PS
    J Biol Inorg Chem; 2012 Dec; 17(8):1197-208. PubMed ID: 22965663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor.
    Zhang Y; Ma Y; Lu HP; Gao JH; Liang CS; Liu CZ; Zou JT; Wang HQ
    Chin Med J (Engl); 2008 Nov; 121(22):2284-9. PubMed ID: 19080333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-linking to an interrupted polypurine sequence with a platinum-modified triplex-forming oligonucleotide.
    Campbell MA; Miller PS
    J Biol Inorg Chem; 2009 Aug; 14(6):873-81. PubMed ID: 19350290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transplatin-conjugated triplex-forming oligonucleotides form adducts with both strands of DNA.
    Campbell MA; Miller PS
    Bioconjug Chem; 2009 Dec; 20(12):2222-30. PubMed ID: 19950917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth inhibition and apoptosis induced by daunomycin-conjugated triplex-forming oligonucleotides targeting the c-myc gene in prostate cancer cells.
    Napoli S; Negri U; Arcamone F; Capobianco ML; Carbone GM; Catapano CV
    Nucleic Acids Res; 2006; 34(2):734-44. PubMed ID: 16449206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of anti-gene and antisense therapeutics on human prostate cancer xenograft in nude mice].
    Zhang Y; Ma Y; Lu HP; Zhou XF; Xie Y; Gao JH; Liang CS
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(29):2073-6. PubMed ID: 19080439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted cross-linking of the human beta-globin gene in living cells mediated by a triple helix forming oligonucleotide.
    Shahid KA; Majumdar A; Alam R; Liu ST; Kuan JY; Sui X; Cuenoud B; Glazer PM; Miller PS; Seidman MM
    Biochemistry; 2006 Feb; 45(6):1970-8. PubMed ID: 16460044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
    Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J
    Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring triplex DNA formation with fluorescence resonance energy transfer between a fluorophore-labeled probe and intercalating dyes.
    Chiou CC; Chen SW; Luo JD; Chien YT
    Anal Biochem; 2011 Sep; 416(1):1-7. PubMed ID: 21609711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of gene expression by triplex-directed psoralen crosslinks.
    Song J; Intody Z; Li M; Wilson JH
    Gene; 2004 Jan; 324():183-90. PubMed ID: 14693383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide conjugates for chromosomal gene targeting by triplex-forming oligonucleotides.
    Rogers FA; Manoharan M; Rabinovitch P; Ward DC; Glazer PM
    Nucleic Acids Res; 2004; 32(22):6595-604. PubMed ID: 15602001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific inhibition of ICAM-1 expression mediated by gene targeting with Triplex-forming oligonucleotides.
    Besch R; Giovannangeli C; Kammerbauer C; Degitz K
    J Biol Chem; 2002 Sep; 277(36):32473-9. PubMed ID: 12080053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigene and antiproliferative effects of a c-myc-targeting phosphorothioate triple helix-forming oligonucleotide in human leukemia cells.
    McGuffie EM; Pacheco D; Carbone GM; Catapano CV
    Cancer Res; 2000 Jul; 60(14):3790-9. PubMed ID: 10919652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA damage produced by 125I-triplex-forming oligonucleotides as a measure of their successful delivery into cell nuclei.
    Panyutin IV; Sedelnikova OA; Bonner WM; Panyutin IG; Neumann RD
    Ann N Y Acad Sci; 2005 Nov; 1058():140-50. PubMed ID: 16394133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific block of androgen receptor activity by antisense oligonucleotides.
    Hamy F; Brondani V; Spoerri R; Rigo S; Stamm C; Klimkait T
    Prostate Cancer Prostatic Dis; 2003; 6(1):27-33. PubMed ID: 12664061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer.
    Jacob S; Nayak S; Fernandes G; Barai RS; Menon S; Chaudhari UK; Kholkute SD; Sachdeva G
    Endocr Relat Cancer; 2014 Jun; 21(3):473-86. PubMed ID: 24812058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of clustered 2'-O-(2-aminoethyl) residues for the gene targeting activity of triple helix-forming oligonucleotides.
    Puri N; Majumdar A; Cuenoud B; Miller PS; Seidman MM
    Biochemistry; 2004 Feb; 43(5):1343-51. PubMed ID: 14756571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triplex-forming oligonucleotides can modulate aquaporin-5 gene expression in epithelial cells.
    Delporte C; Panyutin IG; Sedelnikova OA; Lillibridge CD; O'Connell BC; Baum BJ
    Antisense Nucleic Acid Drug Dev; 1997 Oct; 7(5):523-9. PubMed ID: 9361911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting chromosomal sites with locked nucleic acid-modified triplex-forming oligonucleotides: study of efficiency dependence on DNA nuclear environment.
    Brunet E; Corgnali M; Cannata F; Perrouault L; Giovannangeli C
    Nucleic Acids Res; 2006; 34(16):4546-53. PubMed ID: 16951289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.